Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Center for Sleep and Circadian Neurobiology, University of Pennsylvania, Philadelphia, PA, USA.
J Clin Hypertens (Greenwich). 2019 Oct;21(10):1580-1590. doi: 10.1111/jch.13689. Epub 2019 Sep 18.
Many patients with obstructive sleep apnea (OSA), but not all, have a reduction in blood pressure (BP) with positive airway pressure (PAP) treatment. Our objective was to determine whether the BP response following PAP treatment is related to obesity. A total of 188 adults with OSA underwent 24-hour BP monitoring and 24-hour urinary norepinephrine collection at baseline. Obesity was assessed by waist circumference, body mass index, and abdominal visceral fat volume. Participants adherent to PAP treatment were reassessed after 4 months. Primary outcomes were 24-hour mean arterial pressure (MAP) and 24-hour urinary norepinephrine level. Obstructive sleep apnea participants had a significant reduction in 24-hour MAP following PAP treatment (-1.22 [95% CI: -2.38, -0.06] mm Hg; P = .039). No significant correlations were present with any of the 3 obesity measures for BP or urinary norepinephrine measures at baseline in all OSA participants or for changes in BP measures in participants adherent to PAP treatment. Changes in BP measures following treatment were not correlated with baseline or change in urinary norepinephrine. Similar results were obtained when BP or urinary norepinephrine measures were compared between participants dichotomized using the sex-specific median of each obesity measure. Greater reductions in urinary norepinephrine were correlated with higher waist circumference (rho = -0.21, P = .037), with a greater decrease from baseline in obese compared to non-obese participants (-6.26 [-8.82, -3.69] vs -2.14 [-4.63, 0.35] ng/mg creatinine; P = .027). The results indicate that the BP response to PAP treatment in adults with OSA is not related to obesity or urinary norepinephrine levels.
许多阻塞性睡眠呼吸暂停(OSA)患者,但不是全部,在接受正压通气(PAP)治疗后血压(BP)降低。我们的目的是确定 PAP 治疗后血压反应是否与肥胖有关。共有 188 名 OSA 成年人在基线时接受了 24 小时血压监测和 24 小时尿去甲肾上腺素收集。肥胖通过腰围、体重指数和腹部内脏脂肪体积来评估。坚持 PAP 治疗的参与者在 4 个月后重新评估。主要结局是 24 小时平均动脉压(MAP)和 24 小时尿去甲肾上腺素水平。与 PAP 治疗后 24 小时 MAP 显著降低(-1.22 [95% CI:-2.38,-0.06] mmHg;P =.039)。在所有 OSA 参与者中,基线时的任何 3 种肥胖指标与 BP 或尿去甲肾上腺素指标均无显著相关性,在坚持 PAP 治疗的参与者中,BP 指标的变化也无相关性。治疗后 BP 指标的变化与基线或尿去甲肾上腺素的变化无关。当根据每个肥胖指标的性别特异性中位数将参与者分为两组时,BP 或尿去甲肾上腺素指标也存在类似的结果。尿去甲肾上腺素的减少与腰围的增加呈正相关(rho = -0.21,P =.037),与肥胖参与者相比,基线时的下降幅度更大(-6.26 [-8.82,-3.69] 与 -2.14 [-4.63,0.35] ng/mg 肌酐;P =.027)。结果表明,成人 OSA 患者对 PAP 治疗的血压反应与肥胖或尿去甲肾上腺素水平无关。